Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege study

Basit Öğe Kaydı
dc.authoridCandevir, Aslihan/0000-0001-9340-516X
dc.authoridDemirdal, Tuna/0000-0002-9046-5666
dc.contributor.authorSipahi, Oguz Resat
dc.contributor.authorMermer, Sinan
dc.contributor.authorDemirdal, Tuna
dc.contributor.authorUlu, Ashhan Candevir
dc.contributor.authorFillatre, Pierre
dc.contributor.authorOzcem, Selin Bardak
dc.contributor.authorKaya, Safak
dc.date.accessioned2025-01-27T20:20:21Z
dc.date.available2025-01-27T20:20:21Z
dc.date.issued2018
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjectives: In this study we retrospectively reviewed A. baumannii meningitis cases treated with tigecycline including regimens and evaluated the efficacy of tigecycline in the therapy. Patients and Methods: Study was performed in seven tertiary-care educational hospitals from five cities of Turkey and one center from France. We extracted data and outcomes of all adult (aged > 18) patients with culture proven A. baumannii meningitis treated with tigecycline including antibiotic therapy until April 2016. Results: A total of 23 patients (15 male and eight female) fulfilled our inclusion criteria. All Acinetobacter strains were carbapenem-resistant and susceptible to tigecycline. Six cases received tigecycline monotherapy while 17 received tigecycline including combination therapy (10 with colistin, 4 with netilmicin, 3 with amikacin, 4 with meropenem). Seven of 23 cases (30%) died during the tigecycline including therapy (1 in monotherapy, 4 in colistin, 2 in netilmicin, 1 amikacin, one case received tigecycline + netilmicin followed by tigecycline + colistin). Hence, overall end of treatment (EOT) success was 70%. However, since further 27% died due to additional nosocomial infections, overall clinical success (relieved symptoms at the EOT and one-month post therapy survival without any relapse or reinfection) decreased to 43%. Conclusion: We conclude that tigecycline may be an alternative in the salvage treatment of nosocomial multi drug-resistant Acinetobacter spp. meningitis. Acinetobacter spp. Meningitis.
dc.identifier.doi10.1016/j.clineuro.2018.06.008
dc.identifier.endpage38
dc.identifier.issn0303-8467
dc.identifier.issn1872-6968
dc.identifier.pmid29960893
dc.identifier.scopus2-s2.0-85049096311
dc.identifier.scopusqualityQ2
dc.identifier.startpage31
dc.identifier.urihttps://doi.org/10.1016/j.clineuro.2018.06.008
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21679
dc.identifier.volume172
dc.identifier.wosWOS:000442980000006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Bv
dc.relation.ispartofClinical Neurology and Neurosurgery
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectAcinetobacter baumannii
dc.subjectMeningitis
dc.subjectGlycylcycline
dc.subjectMultidrug resistant bacteria
dc.subjectCarbapenem-resistant
dc.titleTigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu